MBK Partners pursues Chinese pharmaceuticals firm

The private equity firm will acquire Singapore-listed Chinese drug maker, AsiaPharm, for $252 million. Shareholders respond by pushing the traded share price up to near offer level.

North Asia focused private equity firm, MBK Partners, has announced its tender offer to buy 100% of AsiaPharm Group and delist the target at an equity value of S$357.4 million $252 million. The price is a 20 times earnings multiple and around a 30% premium to AsiaPharm's recent traded prices.

MBK, which is most closely associated with partner Michael Kim who is ex-Carlyle, is making the offer in consortium with members of the management team of...

To continue reading, please login or register for free

Click for more on: mbk partners | asiapharm | delisting

Print Edition

FinanceAsia Print Edition


  • Green Bonds Southeast Asia

    25 May 2017  |  Singapore
    With Green Bonds globally reaching USD200 billion outstanding in 2016, from as little as 30bn just 4 years ago, can SE Asia corporations and ...
  • 2nd Compliance Summit Southeast Asia

    17 August 2017  |  Singapore
    The 2017 Compliance Summit Southeast Asia will take an in-depth look at the key compliance considerations today with a focus on regulation and new ...